NASDAQ · Biotechnology

Molecular Partners AG (MOLN) Stock

$3.91 -2.25% NASDAQ: MOLN Healthcare

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology.

Valuation

MetricValue
Price$3.91
Market Cap$146.67M
P/E Ratio-2.08
P/B Ratio1.78
P/S Ratio0.00
EPS (TTM)$-1.65
52-Week High$5.36
52-Week Low$3.41
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-66.19%
ROA-66.25%
ROCE-70.20%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.05
Current Ratio9.42

Annual Financials (USD)

Metric20212022202320242025
Revenue$9.0M$190.0M$7.0M$5.0M$0
Operating Profit$-63.0M$117.0M$-61.0M$-61.0M$-58.0M
Net Profit$-64.0M$118.0M$-62.0M$-54.0M$-62.0M
EPS$-2.06$3.54$-1.89$-1.59$-1.65
Op Margin-679.7%61.5%-868.3%-1231.7%—

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$173.0M$262.0M$198.0M$159.0M$102.0M
Total Liabilities$65.0M$27.0M$22.0M$17.0M$22.0M
Cash$72.0M$88.0M$67.0M$64.0M$83.0M
Borrowings$6.0M$5.0M$4.0M$2.0M$4.0M

Latest News

Molecular Partners Doses First Patients in Phase 2 Study of Biliary Tract Cancer Therapy MT Newswires · Jul 16, 2026 Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma GlobeNewswire · Jul 16, 2026 Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference GlobeNewswire · Jul 15, 2026 Molecular Partners Makes Progress on Radiotherapy Cancer Candidates MT Newswires · Jul 6, 2026 Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics GlobeNewswire · Jul 6, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-91.0M$119.0M$-59.0M$-59.0M$-51.0M
Investing Cash Flow$-24.0M$-103.0M$44.0M$40.0M$72.0M
Financing Cash Flow$0$0$0$-2.0M$0
Net Cash Flow$-62.0M$16.0M$-21.0M$-3.0M$19.0M
Free Cash Flow$-92.0M$117.0M$-60.0M$-60.0M$-52.0M

Valuation & Return Ratios

MetricValue
PEG Ratio-0.32
EV / EBITDA-1.09
FCF Yield-39.55%
Quick Ratio9.42
Interest Coverage-1729.87
Return 1Y9.52%
Return 3Y-40.21%
Return 5Y-78.68%

Ownership

Insiders Held0.00%
Institutions Held9.58%
Institutions Float Held9.58%
Institutional HolderSharesReport Date
Suvretta Capital Management, LLC2,221,4942026-03-31
BVF Inc.1,353,9682026-03-31
Smartharvest Portfolios, LLC15,5432026-03-31
Morgan Stanley3672026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALEC $1.52 +0.33% -1.58 $168.20M 0.00%
APLTApplied Therapeutics, Inc. $0.10 +0.00% -0.24 $14.86M 0.00%
CRBP $9.11 +0.33% -1.95 $168.79M 0.00%
CRDF $0.81 -2.98% -2.58 $53.22M 0.00%
ELTXElicio Therapeutics, Inc. $3.01 +0.17% -1.27 $57.29M 0.00%

About Molecular Partners AG

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, specializing in the identification, advancement, and commercialization of innovative therapeutic proteins. The firm's pipeline includes a range of product candidates, many of which utilize its proprietary DARPin® technology. Key developments include Abicipar, a DARPin therapeutic in Phase III clinical trials for addressing neovascular wet age-related macular degeneration and diabetic macular edema. In the infectious disease space, they are advancing MP0420, a multi-specific DARPin therapeutic targeting the SARS-CoV-2 virus, and MP0423 for COVID-19 treatment. Their oncology programs feature MP0310, currently in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist designed to stimulate immune cells within tumors, which is undergoing Phase I clinical trials; and MP0274, also in Phase I, for HER2-positive cancers. Additional therapeutic candidates encompass MP0533, a CD3 T cell agent for acute myeloid leukemia, and MP0250, engineered to extend drug half-life by interacting with vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin. Molecular Partners AG has established significant partnerships and collaboration agreements with various entities, such as Novartis AG for the development, manufacturing, and commercialization of DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and a discovery alliance in ophthalmology with AbbVie Inc., in addition to other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Molecular Partners AG is headquartered in CH.

Molecular Partners AG (MOLN) stock trades at $3.91 with a market capitalization of $146.67M. The stock is valued at a price-to-earnings (P/E) ratio of -2.08, price-to-book of 1.78, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $3.41 and $5.36, and currently trades 27.1% below its 52-week high.

On profitability, Molecular Partners AG generates a return on equity (ROE) of -66.19%, return on capital employed of -70.20%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.molecularpartners.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides